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Introduction: Management of sedation, analgesia, and anxiolysis are cornerstone therapies in the
emergency department (ED). Dexmedetomidine (DEX), a central alpha-2 agonist, is increasingly
being used, and intensive care unit (ICU) data demonstrate improved outcomes in patients
with respiratory failure. However, there is a lack of ED-based data. We therefore sought to: 1)
characterize ED DEX use; 2) describe the incidence of adverse events; and 3) explore factors
associated with adverse events among patients receiving DEX in the ED.
Methods: This was a single-center, retrospective, cohort study of consecutive ED patients
administered DEX (January 1, 2017–July 1, 2019) at an academic, tertiary care ED with an annual
census of ~90,000 patient visits. All included patients (n= 103) were analyzed for characterization
of DEX use in the ED. The primary outcome was a composite of adverse events, bradycardia and
hypotension. Secondary clinical outcomes included ventilator-, ICU-, and hospital-free days, and
hospital mortality. To examine for variables associated with adverse events, we used a multivariable
logistic regression model.
Results: We report on 103 patients. Dexmedetomidine was most commonly given for acute
respiratory failure, including sedation for mechanical ventilation (28.9%) and facilitation of noninvasive ventilation (17.4%). Fifty-four (52.4%) patients experienced the composite adverse
event, with hypotension occurring in 41 patients (39.8%) and bradycardia occurring in 18 patients
(17.5%). Dexmedetomidine was stopped secondary to an adverse event in eight patients (7.8%).
Duration of DEX use in the ED was associated with an increase adverse event risk (adjusted odds
ratio, 1.004; 95% confidence interval, 1.001, 1.008).
Conclusion: Dexmedetomidine is most commonly administered in the ED for patients with acute
respiratory failure. Adverse events are relatively common, yet DEX is discontinued comparatively
infrequently due to adverse events. Our results suggest that DEX could be a viable option for
analgesia, anxiolysis, and sedation in ED patients. [West J Emerg Med. 2021;22(5)1202–1209.]

INTRODUCTION
The management of sedation, analgesia, and anxiolysis
are critically important principles in the emergency department
(ED). Dexmedetomidine (DEX) is a centrally acting and
selective alpha-2 adrenoreceptor agonist, which inhibits
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norepinephrine release by binding to presynaptic alpha-2
receptors. It provides sedation, anxiolysis, and analgesia via
receptors in the brainstem and spinal cord.1,2 Furthermore, DEX
does not cause respiratory depression, making it an attractive
agent for the management of multiple patient populations.
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In patients with acute respiratory failure, data from
mechanically ventilated intensive care unit (ICU) patients have
demonstrated improved outcomes with DEX, when compared to
benzodiazepines, including a reduction in delirium and ventilator
duration.2-4 In ICU patients who cannot tolerate non-invasive
positive pressure ventilation (NIPPV), DEX has been shown
to be effective at facilitating NIPPV and may be associated
with improved outcomes (ie, reduced intubation rates and ICU
length of stay).1,5 However, there is a lack of data from the ED
domain regarding DEX use in patients with acute respiratory
failure. Other descriptions of DEX use in the ED include alcohol
withdrawal and procedural sedation. Although the data are
limited, a few studies have shown that DEX may reduce the need
for endotracheal intubation in patients with alcohol withdrawal,
and be a safe and effective procedural sedation agent.6-9
Given the lack of data and trials regarding DEX use
in the ED, there is a significant knowledge gap and lack of
familiarity regarding the use of this agent. Furthermore, as
DEX has consistently been shown to increase the incidence
of hypotension and bradycardia, its safety profile in the ED
during routine use is unknown as well. We conducted this
study with several objectives in mind: 1) to characterize the
use of DEX in the ED; 2) describe the incidence of adverse
events in the ED population; and 3) explore factors associated
with adverse events among patients receiving DEX in the ED.
METHODS
Study Design
This was a single-center, retrospective, cohort study and is
reported in accordance with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) Statement
(see supplemental Table S1).10 The study was approved
by the Human Research Protection Office at the principal
investigator’s institution with waiver of informed consent.
There was no financial support or funding organization
associated with the study.

What do we already know about this issue?
Dexmedetomidine (DEX) provides sedation,
anxiolysis, and analgesia and is effective in various
clinical situations. However, data is sparse from the
emergency department (ED) domain.
What was the research question?
How is DEX used in the ED, and what is the
incidence of adverse events associated with its use?
What was the major finding of the study?
Dexmedetomidine is used primarily in respiratory
failure (46.3% of cases). While adverse events
are common (52.4% of cases), they are of
questionable clinical significance.
How does this improve population health?
The use of dexmedetomidine could be an
important adjunct in the care of multiple patient
cohorts in the ED.

were eligible for inclusion. Inclusion criteria were 1) age ≥ 18
years; and 2) the receipt of DEX in the ED for any indication.

Study Setting and Population
The study was conducted at an academic, universityaffiliated teaching hospital with an annual ED census of
approximately 90,000 patient visits. Given the clinical outcome
data regarding DEX, an order-set and protocol was introduced
in the ED in 2017. This protocol advocated for a static DEX
dose of 0.4 micrograms/kilogram/hour (mcg/kg/hour) in nonintubated patients. In mechanically ventilated patients, the
protocol advocated for a starting dose of 0.7 mcg/kg/hour, with
a recommended titration of 0.1 mcg/kg/hour every 45 minutes,
up to a maximum dose of 1.5 mcg/kg/hour. Titration was by
physician order, and not titratable by the nurse. Bolus doses of
DEX were not recommended by the protocol, nor given during
the study period. Over a 30-month period (January 1, 2017–July
1, 2019), all consecutive patients with an order to receive DEX
were identified via electronic health record (EHR) query and
Volume 22, no. 5: September 2021
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Study Protocol
Participant Selection and Data Collection
We identified patients with an order for DEX as receiving
DEX in the ED by registry query, which was verified by
review of the EHR. We excluded patients who did not
actually receive DEX , as well as duplicate patients in the
registry. All measurement and clinical data were gathered
from the EHR using a standardized data collection form
(created a priori), collated into an Excel 2016 (Microsoft
Corporation, Redmond, WA, 2016) data management file,
and exported to SPSS version 26, 2019 (IBM Corporation,
Armonk, NY,) for management and data analysis. Prior
to analysis, we checked the database for out-of-range and
implausible values, and rechecked data as needed in the EHR
to ensure accuracy. Baseline characteristics included the
following: age; gender; race; body mass index; pre-existing
comorbid conditions; disposition data; initial vital signs in
the ED; and select laboratory values. Comorbid conditions
were dementia, diabetes mellitus, cirrhosis, heart failure,
end-stage renal disease, chronic obstructive pulmonary
disease, immunosuppression, malignancy, alcohol abuse, and
psychiatric illness (ie, schizophrenia, bipolar disorder, major
depression, or generalized anxiety disorder). Laboratory
values included lactate, creatinine, bilirubin, platelets,
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hemoglobin, and blood gases. The ED process of care
variables included length of stay, vasopressor use, and need
for mechanical ventilation.
We collected all DEX-related data in the ED including the
following: indication for its use (per clinician documentation
in the ED); time from ED arrival to order and time from order
to drug administration; duration of use in the ED; dosing; and
mental status (Richmond Agitation-Sedation Scale [RASS[
or Glasgow Coma Scale [GCS] at initiation. Additionally, we
collected vital signs at initiation and their lowest values during
drug infusion, and the number of patients in whom DEX was
stopped in the ED, as well as co-administered analgesics and
sedatives in the ED.
We collected details on adverse events and the treatment
variables surrounding adverse events. The primary adverse events
of interest included the incidence of hypotension and bradycardia.
Similar to a prior large, randomized trial, hypotension was
defined as a systolic blood pressure <80 millimeters mercury
(mm Hg), a diastolic blood pressure <50 mm Hg, or > 30%
decrease from baseline (systolic, diastolic, or mean arterial
pressure).3 Bradycardia was also defined based on prior trials, and
included a heart rate < 40 beats per minute, < 60 beats per minute,
or > 30% decrease from baseline.3,4 We also collected data
regarding the need for vasoactive medications or fluid boluses
after DEX initiation. If vasoactive medications or fluid boluses
were given prior to DEX inititation, this was not counted as event
secondary to DEX use. Finally, the cessation of DEX due to an
adverse event was obtained from clinician documentation, and
determined in the following manner: cessation due to hypotension
and/or bradycardia, as defined in adverse events; or if cessation
occurred due to inadvertent extubation.
An a priori subgroup of interest were the patients
requiring mechanical ventilation in the ED.
Outcomes
We analyzed all included patients for characterization
of DEX in the ED. The primary outcome of interest was the
incidence of hypotension and bradycardia related to DEX use.
Other clinical outcomes of interest included the incidence
of acute brain dysfunction on ICU day 1 (delirium and
coma), ventilator-, ICU- and hospital-free days, and hospital
mortality. Coma was defined as having a RASS of -4 or -5 for
every measurement while in the ICU. “Free” days account
for both time (ie, duration of ventilation or lengths of stay)
and mortality and are indexed to study day 28. In participants
who survived 28 days, “-free” days are defined as 28 minus
duration of ventilation (ventilator-free days) or length of
stay (ICU- and hospital-free days). Participants who did not
survive 28 days were assigned zero “-free” days.
Analysis
Patient characteristics are reported using descriptive
statistics, including mean (standard deviation [SD])
and median (interquartile range [IQR]), and frequency
Western Journal of Emergency Medicine

distributions. We compared continuous variables using
independent samples t-test or Mann-Whitney U test, whereas
categorical variables were compared using chi-square test or
Fisher’s exact test. We assessed the normality of the data by
inspection of Q-Q plots and the Kolmogorov-Smirnov test.
For the purposes of this analysis, the primary outcome
of adverse events was a composite outcome of hypotension
or bradycardia. To examine for potential variables associated
with adverse events we used a multivariable logistic regression
model. In anticipation of a small number of events, we chose
a parsimonious model and followed recommendations to
select covariates a priori.11 We therefore selected the following
predictors for the model: 1) vasopressor infusion in the ED;
2) DEX duration in the ED; 3) heart rate at initiation of DEX;
and 4) mechanical ventilation use in the ED. These variables
were chosen for the following reasons: 1) Patients in shock
may be more prone to experience hypotension related to DEX
use; 2) a longer duration of use would allow greater time for
adverse events to occur; 3) a lower baseline heart rate may
lead to a higher incidence of bradycardia; and 4) mechanically
ventilated patients are sicker and typically require more
sedation than non-intubated patients, therefore predisposing
them to a higher complication rate.
All tests were two-tailed with an alpha of 0.05 for statistical
significance. As the study design is a retrospective cohort study
over a fixed time frame, the sample size was limited to the
number of patients receiving DEX during the course of routine
care in the ED. Based on randomized trials examining DEX use
in mechanically ventilated patients, we expected an adverse event
rate ranging anywhere from 20-50%.2-4 Assuming an estimated
event (ie, composite adverse event) per covariable ratio of 10:1
necessary for multivariable logistic modeling, we assumed a
sample size of 100 patients would be adequate to describe DEX
use in the ED and explore factors associated with adverse events,
in a hypothesis-generating multivariable model.12,13
RESULTS
A total of 103 patients were included in the study, and
Figure 1 shows the study flow and final study population.
Baseline characteristics are reported in Table 1. There was a

Figure 1. Flow diagram of included patients who had orders for
dexmedetomidine.
ED, emergency department.
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Table 1. Characteristics of included study participants.
Baseline characteristics

All subjects
(n = 103)

No adverse event
(n = 54)

Adverse event
(n = 49)

P

Age (years)

54 (37-65)

55 (42-65)

54 (35-65)

0.692

Female, n (%)

39 (32.2)

23 (42.6)

16 (32.7)

0.299

BMI

27.0 (22.4-35.0)

29.1 (23.8-35.0)

25.1 (21.1-35.8)

0.248

Black

52 (43.0)

27 (50.0)

25 (51.0)

0.918

White

51 (42.1)

27 (50.0)

24 (49.0)

Dementia

3 (2.5)

1 (1.9)

2 (4.1)

0.502

Diabetes mellitus

31 (25.6)

17 (31.5)

14 (28.6)

0.748

Cirrhosis

7 (5.8)

4 (7.4)

3 (6.1)

0.796

Heart failure

16 (13.2)

10 (18.5)

6 (12.2)

0.380

ESRD

5 (4.9)

4 (7.4)

1 (2.0)

0.206

COPD

22 (18.2)

14 (25.9)

8 (16.3)

0.235

Alcohol abuse

27 (22.3)

16 (29.6)

11 (22.4)

0.408

Illicit drug abuse

29 (24.0)

17 (31.5)

12 (24.5)

0.431

Psychiatrica

16 (13.2)

6 (11.1)

10 (20.4)

0.193

ICU

97 (80.2)

50 (92.6)

47 (95.9)

Floor

Race, n (%)

Comorbidities, n (%)

Disposition Data, n (%)
Admit Location

0.472
6 (5.0)

4 (7.4)

2 (4.1)

Temperature (oC)

36.7 (36.4-37.1)

36.6 (36.3-37.0)

36.7 (36.5-37.2)

0.164

Heart rate (bpm)

107 (23)

104 (23)

109 (22)

0.249

Respiratory Rate (bpm)

23 (7)

23 (7)

23 (7)

0.684

Systolic pressure (mm Hg)

145 (30)

143 (26)

146 (33)

0.646

Diastolic pressure (mm Hg)

89 (22)

89 (21)

88 (23)

0.848

Peripheral oxygen saturation (%)

94 (8)

96 (50)

93 (10)

0.018

Lactate (mmol/L)

2.3 (1.4-3.6)

2.3 (1.4-3.5)

2.2 (1.3-4.7)

0.900

Creatinine (mg/dL)

1.0 (0.8-1.3)

1.1 (0.8-1.3)

1.0 (0.7-1.2)

0.289

Bilirubin (mg/dL)

0.4 (0.3-0.6)

0.4 (0.3-0.6)

0.4 (0.3-0.8)

0.616

pH (n = 78)

7.31 (0.13)

7.31 (0.11)

7.30 (0.14)

0.560

Partial pressure arterial oxygen (n=34)

150 (76)

144 (61)

157 (93)

0.628

Partial pressure arterial or venous carbon dioxide
(n = 78)

48 (17)

45 (11)

52 (21)

0.086

SOFA score

1.0 (0-4.0)

1.0 (0-3.0)

1.0 (1.0-4.0)

0.697

Length of stay (hours)

7.1 (4.7-9.6)

6.7 (4.5-8.7)

7.9 (5.2-10.3)

0.101

Vasopressor infusion, n (%)

14 (11.6)

4 (7.4)

10 (20.4)

0.055

ED process of care variables

Mechanically ventilated, n (%)
40 (33.1)
24 (44.4)
16 (32.7)
0.220
a
Psychiatric if diagnosed with schizophrenia, bipolar, major depression, or generalized anxiety disorder
Continuous variables are reported as mean (standard deviation) and median (interquartile range).
BMI, body mass index; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit;
C, Centigrade; bpm, beats per minute; bpm, breaths per minute; mm Hg, millimeters mercury; mmol/L, millimoles per liter; mg/dL,
milligrams per deciliter; SOFA, sequential organ failure assessment; ED, emergency department.
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statistical difference in peripheral oxygen saturation (mean
[SD]) between patients experiencing an adverse event vs those
who did not (93 [10] vs 96 [50], P = 0.018]. There were no
other significant differences between patients experiencing an
adverse event vs those who did not.
Dexmedetomidine-related variables are shown in Table
2. Acute respiratory failure, including mechanical ventilation

(28.9%) and NIPPV (17.4%), was the most common
indication for DEX, followed by control of agitation (14.9%)
and anxiety (11.6%). The median starting dose in the ED
was 0.4 mcg/kg/hour (0.2 – 0.4). However, variability in
starting dose did exist, as 16 patients were started at a dose
of 0.7 mcg/kg/hour or higher (3 patients ≥ 1.0 mcg/kg/hour).
Median infusion rate remained at 0.4 mcg/kg/hour for the

Table 2. Dexmedetomidine dosing and sedation characteristics.
All subjects
(n = 103)

Variable

No adverse event
(n = 54)

Adverse event
(n = 49)

P

Indication for dexmedetomidine, n (%)*

0.847

Procedural sedation

4 (3.3)

2 (3.7)

2 (4.1)

Alcohol withdrawal

9 (7.4)

5 (9.3)

4 (8.2)

Anxiolysis

14 (11.6)

5 (9.3)

9 (18.4)

Psychosis/agitation

18 (14.9)

10 (18.5)

8 (16.3)

Facilitation of NIPPV

21 (17.4)

10 (18.5)

11 (2.4)

Sedation for mechanical ventilation

35 (28.9)

21 (38.9)

14 (28.6)

Other

2 (1.7)

1 (1.9)

1 (2.0)

Time from ED arrival to order
(minutes)

156 (64 – 317)

170 (73 – 317)

136 (42 – 333)

0.722

Time from order to administration
(minutes)

26 (11 – 55)

42 (16 – 60)

21 (9 – 32)

0.021

Duration of dexmedetomidine in ED
(minutes)

139 (74 – 211)

122 (69 – 207)

164 (96 – 240)

0.041

Starting dose in ED (mcg/kg/hour)

0.4 (0.2 – 0.4)

0.4 (0.2 – 0.5)

0.4 (0.2 – 0.4)

0.267

RASS at initiation of
dexmedetomidine (n= 29)

1 (0 – 3)

1 (-1 to 3)

1 (0 - 2)

0.811

GCS at initiation of dexmedetomidine
(n= 40)

13 (10 – 15)

13 (11 – 15)

13 (9 – 14)

0.366

Co-administered analgesics and
sedatives, n (%)

0.248

Fentanyl

41 (39.8)

23 (42.6)

18 (36.7)

Propofol

28 (27.2)

16 (29.6)

12 (24.5)

Midazolam

34 (33.0)

17 (31.5)

17 (34.7)

Ketamine

38 (36.9)

18 (33.3)

20 (40.8)

Lorazepam

32 (31.1)

15 (27.8)

17 (34.7)

Haloperidol

25 (24.3)

14 (25.9)

11 (22.4)

Vital signs

At
initiation

Lowest
during
infusion

At
Initiation

Lowest
during
infusion

At
Initiation

Lowest
during
infusion

At
initiation

Lowest
during
infusion

Heart rate (bpm)

105 (23)

86 (21)

102 (21)

91 (22)

108 (25)

81 (19)

0.163

0.010

Respiratory rate (bpm)

23 (7)

20 (18)

24 (7)

20 (6)

23 (7)

18 (5)

0.697

0.051

Systolic blood pressure (mm Hg)

140 (29)

112 (25)

141 (27)

124 (21)

138 (32)

99 (22)

0.606

<0.001

Diastolic blood pressure (mm Hg)

85 (24)

68 (18)

86 (20)

77 (16)

84 (27)

58 (16)

0.740

<0.001

Mean arterial pressure (mm Hg)

101 (24)

82 (19)

102 (21)

92 (16)

100 (27)

71 (16)

0.796

<0.001

Dexmedetomidine infusion stopped
in ED, n (%)a

22 (18.2)

11 (20.4)

11 (22.4)

0.797

Eighteen patients were documented as having an additional secondary indication for dexmedetomidine use.
NIPPV, non-invasive positive pressure ventilation; ED, emergency department; mcg/kg/hour, micrograms/kilogram/hour; RASS, Richmond
Agitation-Sedation Scale; GCS, Glasgow Coma Scale; bpm, beats per minute; bpm, breaths per minute; mm Hg, millimeters mercury.
a
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first four hours, and the highest median infusion rate was 0.7
(0.4 – 0.9), demonstrating that, overall, relatively low doses
of DEX were used in the ED. Dexmedetomidine was stopped
in the ED in 22 (18.2%) patients. Co-administered analgesics
and sedatives included fentanyl (39.8%); ketamine (36.9%);
midazolam (33%); lorazepam (31.1%); haloperidol (28.2%);
and propofol (27.2%).
Adverse events and clinical outcomes are reported in
Table 3. Fifty-four (52.4%) patients experienced the composite
adverse event, with hypotension occurring in 41 patients

patients with no adverse event (mean [SD]), were as follows:
ventilator-free days, (20.4 [10.5] vs 22.6 [8.7], P = 0.44); ICUfree days, (21.7 [8.1] vs 21.3 [8.4], P = 0.83),; and hospitalfree days (18.5 [8.1] vs 17.5 [8.7], P = 0.53). Mortality among
patients experiencing an adverse event when compared to those
with no adverse event was 10.2% vs 9.3%, P = 0.87.
Table 4 shows the multivariable logistic regression analysis
for predictors of the composite primary outcome. Duration of
DEX use in the ED was associated with an increased risk for
hypotension or bradycardia (adjusted odds ratio [aOR], 1.004;
95% CI, 1.001, 1.008), while vasopressor infusion in the ED was
associated with a decrease risk (aOR, 0.21; 95% CI, 0.05, 0.82).

Table 3. Adverse events and clinical outcomes.
Variable
All subjects (n = 103)
Hypotension, n (%)

Table 4. Multivariable logistic regression analysis with a composite
of hypotension and bradycardia as the dependent variable.

41 (39.8)

SBP <80 mm Hg

8 (7.8)

DBP <50 mm Hg

14 (13.6)

>30% decrease from baseline*

19 (18.4)

Vasopressor
infusion in the ED

0.21

0.05 –
0.82

0.70

0.025

<60 bpm

18 (17.5)

1.001 –
1.008

0.01

0.022

0 (0.0)

Dexmedetomidine
duration in the ED

1.004

<40 bpm

Heart rate at
initiation of
dexmedetomidine

1.01

0.99 –
1.03

0.01

0.238

Variables

Bradycardia, n (%)*

Vasoactive medication given after
dexmedetomidine initiated, n (%)

8 (7.8)

Fluid bolus given after
dexmedetomidine initiation, n (%)

12 (11.7)

Cessation of dexmedetomidine due to
adverse event, n (%)

8 (7.8)

Starting dose in ED (mcg/kg/hour)

0.4 (0.2 – 0.4)

63 (61.2)

Coma

0

ICU-free days**

21.5 (8.2)

Hospital-free days

18.0 (8.4)

Hospital mortality, n (%)

10 (9.7)

Standard
error

P

Details regarding the mechanically ventilated subgroup
are provided in supplemental tables S2-4. Overall, the dosing
characteristics and adverse events experienced by mechanically
ventilated patients were similar to the entire cohort.

*Refers to a decrease in systolic, diastolic, or mean arterial
pressure.
**Refers to the 97 patients admitted to the intensive care unit from
the emergency department.
Continuous variables are reported as mean (standard deviation)
and median (interquartile range).
SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm,
beats per minute; ED, emergency department; mcg/kg/hour,
micrograms/kilogram/hour; ICU, intensive care unit.

(39.8%) and bradycardia occurring in 18 patients (17.5%).
Patients experiencing an adverse event were given a fluid bolus
(20.4% vs 3.7%, P <0.01) and vasoactive medications (12.2%
vs 3.7%, P = 0.11) more frequently when compared to patients
without an adverse event. Dexmedetomidine was stopped
secondary to an adverse event in eight patients (7.8%). Clinical
outcomes for patients experiencing an adverse event vs those in
Volume 22, no. 5: September 2021

95% CI

Mechanical
1.63
0.60 –
0.51
0.341
ventilation in the ED
4.40
ED, emergency department; aOR, adjusted odds ratio; CI,
confidence interval.

Acute brain dysfunction on day 1 ICU,
n (%)
Delirium

aOR

DISCUSSION
As sedation and pain control are cornerstone therapies
provided in the ED, and with the increase in use of DEX,
information regarding its use in the ED is critical before
quality improvement or future research can occur. The current
study provides some new information regarding DEX use in
the ED and builds on prior work by examining this agent in
the ED domain.
With respect to our first objective, DEX is used for
diverse indications in the ED, and most commonly for
patients with respiratory failure. This is congruent with
prior work and facilitated by DEX’s analgesic and sedative
properties, without suppression of respiratory drive. The coadministration of other sedatives and analgesics was common,
and could be driven by the known limitations of DEX, such
as slower onset of action. There was a delay in administration
of DEX (156 minutes) and relatively static dosing in the ED.
This is likely driven by the lack of DEX in the ED (ie, ordered
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from pharmacy), as well as the institutional protocol, which
called for no titration (in non-intubated patients) or physicianordered titration (in mechanically ventilated patients).
Going forward, areas for potential improvement could be as
follows: 1) earlier identification of patients who may benefit
from DEX, given the 2.5 hours of elapsed time from patient
arrival to order; and 2) titrated dosing if DEX is tolerated, yet
sedation goals have not been achieved.
Our most important finding relates to the adverse events
experienced by ED patients given DEX. Prior work in difficultto-sedate patients (n = 13) stated that DEX “is not safe in
the ED setting.”14 Our results would suggest otherwise, and
demonstrate that an ED-based DEX protocol can be effectively
implemented. While adverse events were relatively common,
the event rate for DEX use is congruent with that experienced
in large randomized trials.2-4 Also, when placed in the context
of the reported incidence of hypotension with midazolam
(11.6% to 55.7%) and propofol (13.4% to 52.4%) described in
the literature, our results further suggest that DEX compares
favorably in the ED setting.3,15,16 Furthermore, in only eight
patients (7.8%) did physicians stop DEX due to an adverse
event, suggesting that while hypotension and bradycardia
were relatively common, these events were clinically well
tolerated as judged by the treating team. Patients experiencing
adverse events did require more intensive therapy in the ED, as
demonstrated by the administration of more fluid boluses and
vasoactive medications.
There was no statistical difference in patient-centered
clinical outcomes between patients experiencing an adverse
event when compared to those who did not. However, we
urge caution in interpreting these clinical outcome data, given
the small sample size. Contrary to our rationale for including
vasopressors in the multivariable model, vasopressor infusion in
the ED was associated with a lower chance for adverse events. It
is possible that vasopressor titration reduced the risk of reported
hypotension. While our study lacks granular detail on pressor
requirements during DEX infusion, this finding is congruent with
prior work showing that DEX is well tolerated in patients with
shock.17A potentially important finding is the fact that duration
of DEX exposure in the ED was associated with adverse events.
While we lack specific detail on the exact timing of events, these
data suggest the need for ongoing diligent monitoring for safety
while DEX is being used in the ED.
Finally, in our subgroup of mechanically ventilated
patients, the dosing of DEX and adverse events were
comparable to non-intubated patients. While no definitive
conclusions can be drawn from this small sample size, our
findings suggest that DEX use in the ED could be a viable
option going forward.

generalizing these results to other centers, especially those
where DEX use is infrequent in both the ED and ICU. While
to our knowledge this is the largest ED-based DEX study to
date, the small sample size limits any conclusions that can be
drawn from these data. We further emphasize that point with
respect to the subanalysis with an even smaller sample size
and commensurate power limitations secondary to that. Due
to an overall lack of sedation depth documentation, we cannot
comment on the efficacy of DEX use in the ED. Future studies
will need to assess for sedation depth, pain control, and
anxiolysis in a much more granular fashion.
We defined our adverse events based on prior work from
randomized trials on DEX in mechanically ventilated patients.
While our adverse event rate was congruent with prior work,
had our definition differed, the incidence of hypotension and
bradycardia experienced in the ED could be lower than our
current definition. This is especially important when considering
that only eight patients had their DEX infusion stopped because
of an adverse event. We also do not have details on why DEX
was stopped outside of adverse events. It is possible that
DEX was stopped because of inefficacy, or improving clinical
trajectory. Due to the study design, it is impossible to ascribe
causation for the adverse events, as multiple agents were used
in addition to DEX, and we can only describe associations.
Finally, due to the overall low event rate and small sample size,
the results of our multivariable model should be considered
exploratory and hypothesis-generating at this point.

LIMITATIONS
This study has several limitations. This was a
retrospective, single-center study that carries with it all of
the limitations of that design, including limits with respect to
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CONCLUSION
Dexmedetomidine is most commonly administered
in the ED for patients with acute respiratory failure
(ie, those requiring mechanical ventilation or NIPPV).
While adverse events are relatively common, they are of
questionable clinical significance. Our results suggest that
dexmedetomidine can be incorporated effectively into clinical
care in the ED and be a viable option for analgesia, anxiolysis,
and sedation in ED patients, similar to its role in the ICU.
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